anti-vegf

Anti-MouseVEGF-AAntibody (2G11-2A05) is an IgG2a, κ inhibitor antibody derived from rats, targeting and inhibiting mouse VEGF-A.

Anti-VEGF165 VEGFA Antibody (5L924) is a Rabbit IgG monoclonal antibody targeting Human, Cynomolgus VEGF165 VEGFA.

Anti-VEGF165 VEGFA Antibody (4A225) is a Rabbit IgG monoclonal antibody targeting Human, Cynomolgus VEGF165 VEGFA.

Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (K D = 1.05 pM), used for cancer research [1][2].

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

Hb0025 is a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts antitumor effects by inhibiting VEGF activity and facilitating T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. Molecular weight: 170.8 KD.

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody that can be combined with Paclitaxel for cancer research, particularly in studies of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3].

Abicipar pegol (AGN-150998, MP0112), an anti-VEGF DARPin molecule, is a novel class of small ankyrin repeat domain-containing proteins designed for high specificity and affinity targeting. This compound effectively inhibits angiogenesis and vascular permeability, and has been applied in ocular inflammation-related disease studies through intravitreal injections, significantly reducing mean retinal thickness and leakage area [1] [2].